Lung Health Foundation Welcomes Three New Board Members to Strengthen its Mission to Improve the Lung Health of Canadians

The Lung Health Foundation (LHF) is proud to announce the appointment of three new members to its Board of Directors, effective June 26, 2025. These appointments reflect LHF’s deep commitment to person-centered care, informed governance, and financial stability that will help transform lung health outcomes across Canada. Joining the board are Joanna Wilson, a seasoned […]

From breakthroughs to what’s next in lung health

As we reflect on the past year at the Lung Health Foundation, one word stands out: breakthrough.

In 2024–2025, your support helped us reach new heights and our just-released Annual Report tells the full story.

Lung Health Foundation Offers Grants to Help Advocates Grow

Have you or a loved one shared your lung health journey as an advocate with the Lung Health Foundation in the past 18 months? If yes, you may be eligible to apply for our new LHF Advocate Professional Development and Brand Ambassador Grant!

Before the Blaze: 5 Wildfire Preparation Tips from the Lung Health Foundation

Wildfire season is just getting started. Are you taking steps to protect your lung health?

To help our coast-to-coast community prepare, the Lung Health Foundation has created this simple preparation checklist. It will be of special interest to people who live near typical fire zones – but remember, the effects of wildfire smoke can often travel thousands of kilometers away.

Say “Yes” Again: How You Can Help Canadians Living with Asthma Enjoy More of Life

Asthma doesn’t just affect the lungs—it affects moments, memories, and confidence.

For many of the 4.6 million Canadians living with asthma, it’s not just about managing symptoms. It’s about navigating daily life with caution. It’s about hesitating before saying yes to that hike, yes to that dance, or even yes to walking to school on a chilly morning.

New Treatment Option Moving Towards Reimbursement for Adults with Operable Early-Stage NSCLC

Pembrolizumab (Keytruda) is one step closer to being funded via Canada’s various provincial drug plans for the treatment of adults with operable stage II, IIIA, or IIIB (T3 to 4N2) non-small cell lung cancer (NSCLC) to be used with chemotherapy before surgery to shrink the cancer and then used on its own after surgery to help keep the cancer from coming back, if certain conditions are met.